AstraZeneca has recently launched a new global health tech business, Evinova, aimed at streamlining the clinical trial process and making it more accessible for patients. The company identified a market need for these services and decided to fill it with the creation of Evinova.
Evinova will operate as a separate business, financially backed by AstraZeneca. The company will provide global services to CROs and pharmaceutical companies to design, run, and monitor clinical trials. Customers will have access to Evinova’s technology on a revenue-based model.
Through the launch of Evinova, AstraZeneca hopes to address the challenges and inefficiencies in the clinical trial process, ultimately making it easier for patients to participate and improving the overall effectiveness of the trials. This new business venture reflects AstraZeneca’s commitment to advancing healthcare and utilizing technology to improve the drug development process.